Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=4508712 for the full story.

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=4333537 for the full story.

Johnson & Johnson Completes Mentor Tender With 94% Of Shares

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=4325098 for the full story.

The health-care giant reports increasing earnings, despite falling revenue.

Matt Taibbi is one of the few commentators in the mainstream media who is not worried about ‘access’ and has, therefore, been free to write much more critically about the economic crisis and reform efforts on Wall Street. His first piece was a polemic against Goldman Sachs,[More...]

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.[More...]

The BioMedReports.com FDA Calendar database includes over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response letter (CRL) re-submissions to the FDA; and (4) pending clinical trial results.[More...]

In 1964, Donald and Mildred Othmer placed $25,000 in the hands of a young Columbia University MBA graduate. In 1974, the graduate returned to offer them the choice of having their money back, or buying shares in his new company.[More...]

The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x, including: Pfizer (PFE, 7.5x), Eli Lilly (LLY,[More...]

Tom Dorsey and Tammy DeRosier Interview Josh Parker, President of Gargoyle Asset Management

Tom Dorsey and Tammy DeRosier - Continuing the Journey

Tom Dorsey and Tammy Derosier discuss a wide range of topics this Thanksgiving week